LPX Lipoxen

 

TIDMLPX 
 
RNS Number : 7796G 
Lipoxen PLC 
08 February 2010 
 

+---------------------------------+---------------------------------+ 
| For immediate release           |                 8 February 2010 | 
+---------------------------------+---------------------------------+ 
 
 
 
                                  Lipoxen plc 
                          ('Lipoxen' or 'the Company') 
 
            Lipoxen's Polysialylated G-CSF StimuXen(TM) Technology 
                            Granted European Patent 
 
 
Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the 
development of high-value differentiated biologicals, vaccines and siRNA 
delivery, announces that it has been granted patents for its Polysialylated 
G-CSF StimuXen(TM) Technology in six European territories, including the UK, 
Germany, France, Spain, Italy and Switzerland. 
 
This technology is based on polysialic acid (PSA, a polymer occurring naturally 
in humans), which extends a protein's active life. PSA is biodegradable, 
non-immunogenic and non-toxic and is also therefore expected to avoid the 
toxicity attributed to polyethylene glycol (PEG) in PEGylated protein drug 
candidates. 
 
StimuXen(TM) uses Lipoxen's patented PolyXen(TM) technology to attach polysialic 
acid onto the N-terminal of G-CSF to produce polysialylated G-CSF. The patent 
application related to it is recent and has now been granted in Europe. 
Preclinical work with StimuXen(TM) has shown improved pharmacokinetics and 
pharmacodynamics which are similar to those of the longest-acting version of 
G-CSF on the market whose patent expires in 2015. G-CSF generated global sales 
of $5.2B in 2008. 
 
How it works 
 
The G-CSF (granulocyte-colony stimulating factor) stimulates the bone marrow to 
produce more white blood cells (WBC). 
 
A major side effect of chemotherapy is a reduction in the number of WBC which 
can lead to a patient's reduced ability to fight infection, consequent to which 
chemotherapy may be postponed or the dose lowered, neither outcome being optimal 
for the preferred treatment. Prescription of G-CSF acts to protect the body's 
level of WBC during chemotherapy and is usually administered daily for up to 14 
days. 
 
The leading currently available G-CSF therapy is administered once with each 
cycle of chemotherapy. Lipoxen expects that the improved StimuXen(TM) G-CSF will 
have a similar treatment profile. 
 
Commenting on the patent grant, M. Scott Maguire, CEO of Lipoxen, said: "We are 
confident that StimuXen(TM), which is currently in pre-clinical development, 
could be as successful as our two potential billion dollar block-buster products 
in clinical development, SuliXen(TM), a long acting insulin, and ErepoXen(TM), a 
long-acting erythropoietin (EPO) both of which are based on this PolyXen(TM) 
technology." 
 
                                    - Ends - 
 
For further information please contact: 
 
+------------------------------------------+--------------------+ 
| Lipoxen plc                              |     +44 (0)20 7389 | 
|                                          |               5015 | 
+------------------------------------------+--------------------+ 
| M. Scott Maguire, Chief Executive        |                    | 
| Officer                                  |                    | 
+------------------------------------------+--------------------+ 
|                                          |                    | 
+------------------------------------------+--------------------+ 
| Singer Capital Markets (nominated        |     +44 (0)20 3205 | 
| adviser)                                 |               7500 | 
+------------------------------------------+--------------------+ 
| Jeff Keating, Claes Spång                |                    | 
+------------------------------------------+--------------------+ 
|                                          |                    | 
+------------------------------------------+--------------------+ 
| Noble & Company                          |     +44 (0)20 7763 | 
|                                          |               2200 | 
+------------------------------------------+--------------------+ 
| James Bromhead, Sam Reynolds             |                    | 
+------------------------------------------+--------------------+ 
|                                          |                    | 
+------------------------------------------+--------------------+ 
| Buchanan Communications                  |     +44 (0)20 7466 | 
|                                          |               5000 | 
+------------------------------------------+--------------------+ 
| Lisa Baderoon, Catherine Breen           |                    | 
+------------------------------------------+--------------------+ 
 
Notes for Editors 
 
About Lipoxen 
Lipoxen plc is a biopharmaceutical company focused on the development of new and 
improved biologic drugs and vaccines.  Lipoxen has three proprietary patented 
technology platforms: 
 
1) PolyXen - for extending the efficacy and half life of biologic drugs 
2) ImuXen - for creating new vaccines and improving existing vaccines 
3) SiRNAblate - for the delivery of siRNA 
 
Lipoxen's technology is designed to improve the efficacy, safety, stability, 
biological half-life and immunologic characteristics of its products. 
 
Lipoxen has multiple drug and vaccine programmes in development.  Two products 
are in clinical development, SuliXen, a long acting insulin and ErepoXen, a 
long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes 
vaccines against HIV, influenza and malaria and an exclusive license deal with 
Baxter Healthcare for Factor VIII 
 
The Company has a low-risk business model and out-licenses its proprietary 
technologies to biopharmaceutical companies that have strong manufacturing and 
marketing capabilities.  Lipoxen currently has commercial agreements with some 
of the world's leading biotechnology and pharmaceutical companies including 
Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and 
Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and 
management led the GBP2.9 million fundraising that the Company announced in May 
2009. 
 
Lipoxen, which was founded in 1997, now trades on the AIM Market of the London 
Stock Exchange under the ticker symbol LPX. More information can be found at the 
Company's website: www.lipoxen.com. 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCQELFBBLFFBBB 
 

Lipoxen (LSE:LPX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Lipoxen (LSE:LPX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024